Immunotherapy
By Dana Taylor
CAR T-cell therapy is a new type of immunotherapy that uses the patient’s genetically modified immune T-cells to attack cancer cells. In 2017, the FDA approved the first 2 CAR T-cell therapies for several types of blood cancer. Read More ›
By Dana Taylor
Significant developments in the treatment of lung cancer were reported at the 2017 annual meeting of the European Society for Medical Oncology (ESMO) in Madrid, Spain. Read More ›
An interview with Ross Maclean, MD, PhD, Senior Vice President, Head of Medical at Precision Health Economics, Princeton, NJ, about the importance of personalized medicine in the treatment of cancer. Read More ›
By Nick Bryant
A roundup of 4 leading healthcare professionals offers an optimistic outlook on immunotherapy at the Second International Cancer Immunotherapy Conference, titled “Translating Science into Survival.” Read More ›
Welcome to the first Special Edition of CONQUER: the patient voice, which focuses on immunotherapies in cancer. With the recent explosion of new immunotherapies being approved by the FDA for the treatment of patients with cancer, and their promise for improvements in survival and reduced adverse events, every patient with cancer should become familiar with these new therapies and the hope they bring to patients, survivors, and their family members. Read More ›
Dr. Bruce Gershenhorn examines the hope that immunotherapy brings to patients, explaining the current medications available, side effects, and future of this promising therapeutic option. Read More ›
This article includes immunotherapies approved through May 2017. Read More ›
According to the Cancer Research Institute, only 3% to 6% of eligible patients with cancer participate in clinical trials in the United States. Read the reasons why clinical trials are a great option to consider. Read More ›
Catherine Poole breaks down the emerging immunotherapy options for Melanoma, not to be confused with the common skin cancers (basal-cell carcinoma and squamous-cell carcinoma) largely caused by exposure to UV rays. Read More ›
“We are continuing to learn about the ways the immune system interacts with difference types of cancer, including multiple myeloma,” said Dr. Pazdur of the FDA. Read More ›